Novo Nordisk has introduced NovoFine plus 32G 4mm, an ultra-thin, ultra-short pen needle that aims to make injections more comfortable for patients with diabetes.

The NovoFine plus is 4mm in length and is as thin as two human hairs. These features offer patients less pain and a reduced risk of intramuscular injection. The device is compatible with all major pen devices.

Incorporating SuperFlow technology, the NovoFine plus offers patients faster injections that need less force. It has been designed to reduce the risk of bending or breakage.

The SuperFlow technology increases the width of the internal bore without increasing the outer diameter of the needle. This results in the increase of flow rate and a decrease in resistance and force required to deliver the treatment dose through the needle.

The short length of NovoFine plus means it can be inserted into the skin at a 90º angle without the need to create a skin fold before injecting and the flat hub of the needle is designed to make injections more comfortable.

"The triple bevel design of the device may reduce the penetration force required to puncture the skin."

The triple bevel design of the device may reduce the penetration force required to puncture the skin.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Novo Nordisk Device R&D senior vice-president Jesper Klove noted the company knows needle anxiety can be a real barrier when people with diabetes start insulin therapy, and in some people this fear really compromises their treatment.

"Novo Nordisk is committed to improving diabetes care and as part of our broad portfolio within treatment, devices and needles, we’re pleased to provide this new option to people with diabetes," Klove said.

NovoFine plus will be initially launched in Canada and the device will be launched in several other countries during 2014 and 2015.

Image: Image: Novo Nordisk launches NovoFine plus pen needle. Photo: courtesy of Novo Nordisk A/S.